CryoPort, Inc. Common Stock (CYRX) — Analysis Summary
CryoPort, Inc. Common Stock (CYRX) has a market cap of $852.93M with year-over-year revenue growth of -22.9%. Net margin stands at 44.4%. The stock trades at a P/E ratio of -25.3.
Key Takeaways
- Revenue changed -22.9% year-over-year
- Net margin of 44.4%
- P/E ratio of -25.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, CYRX posted revenue growth of -22.9% and trades at a P/E of -25.3.
CryoPort, Inc. Common Stock (CYRX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -18.8x — earnings do not cover interest payments
Net income turned negative after a profitable prior period.
Operating margin at -21.2% — material operating losses
The latest filing shows negative free cash flow.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
738
Headquarters
BRENTWOOD, TN
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.